Filtered By:
Infectious Disease: Herpes
Management: Funding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 50 results found since Jan 2013.
Bacillus Calmette-Gu érin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial
EClinicalMedicine. 2023 Sep 11;64:102203. doi: 10.1016/j.eclinm.2023.102203. eCollection 2023 Oct.ABSTRACTBACKGROUND: Recurrences of herpes simplex virus (HSV) in the orofacial region (herpes labialis or cold sores) impact quality-of-life. We aimed to study whether the bacille Calmette-Guérin (BCG) vaccine can attenuate cold sore recurrences through off-target immunomodulatory effects.METHODS: In this nested randomised controlled trial within the multicentre, phase 3 BRACE trial, 6828 healthcare workers were randomised in 36 sites in Australia, the Netherlands, Spain, the United Kingdom and Brazil, to receive BCG-Denmark ...
Source: Herpes - September 18, 2023 Category: Infectious Diseases Authors: Laure F Pittet Cecilia L Moore Ellie McDonald Simone Barry Marc Bonten John Campbell Julio Croda Margareth Dalcolmo Andrew Davidson Mark W Douglas Kaya Gardiner Amanda Gwee Bruno Jardim Marcus V G Lacerda Michaela Lucas David J Lynn Laurens Manning Robert Source Type: research
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208-X. doi: 10.1016/S2468-1253(23)00208-X. Online ahead of print.ABSTRACTBACKGROUND: Upadacitinib is an oral, selective, and reversible JAK inhibitor with demonstrated efficacy in patients with moderately to severely active ulcerative colitis in a phase 2b induction trial, two phase 3 induction trials (U-ACHIEVE Induction and U-ACCOMPLISH), and a primary analysis of the first 451 patients entering a subsequent maintenance trial (U-ACHIEVE Maintenance). Here, we present overall results from the entire U-ACHIEVE Maintenance population.METHODS: In this randomised, place...
Source: Herpes - September 8, 2023 Category: Infectious Diseases Authors: S éverine Vermeire Silvio Danese Wen Zhou Dapo Ilo Justin Klaff Gweneth Levy Xuan Yao Su Chen Yuri Sanchez Gonzalez Xavier H ébuterne James O Lindsay Peter D R Higgins Qian Cao Hiroshi Nakase Jean-Fr édéric Colombel Edward V Loftus Remo Panaccione Source Type: research
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial
This study provides insights into the design of future CMV vaccine efficacy trials, particularly for the identification of CMV infection using molecular assays.FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA (MSD).PMID:37660711 | DOI:10.1016/S1473-3099(23)00343-2
Source: Herpes - September 3, 2023 Category: Infectious Diseases Authors: Rituparna Das Daniel Bl ázquez-Gamero David I Bernstein Soren Gantt Oliver Bautista Karen Beck Anthony Conlon Daniel I S Rosenbloom Dai Wang Michael Ritter Beth Arnold Paula Annunziato Kevin L Russell V160-002 study group Source Type: research
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis
We report a prespecified interim analysis of primary-series AZD1222 (ChAdOx1 nCoV-19) VE.METHODS: Seven Study Contributors in Europe collected data on individuals aged ≥18 years who were hospitalised with severe acute respiratory infection (June 1st, 2021-September 5th, 2022) and eligible for COVID-19 vaccination prior to hospitalisation. In this test-negative case-control study, individuals were defined as test-positive cases or test-negative controls (SARS-CoV-2 RT-PCR) and were either fully vaccinated (two AZD1222 doses, 4-12 weeks apart, completed ≥14 days prior to symptom onset; no booster doses) or unvaccinated (...
Source: Herpes - August 7, 2023 Category: Infectious Diseases Authors: Wilhelmine Meeraus Leonie de Munter Christen M Gray Akshat Dwivedi Chlo é Wyndham-Thomas Mario Ouwens Wendy Hartig-Merkel Laura Drikite Griet Rebry Antonio Carmona Anke L Stuurman Thi Yen Chi Nguyen Guillermo Mena Ainara Mira-Iglesias Giancarlo Icardi Su Source Type: research
Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
Lancet Reg Health West Pac. 2023 Feb 18;34:100707. doi: 10.1016/j.lanwpc.2023.100707. eCollection 2023 May.ABSTRACTBACKGROUND: Despite the success in decreasing varicella-related disease burden, live-attenuated Oka vaccine strain of varicella-zoster virus (vOka) remains neuro-virulence and may establish latency and reactivate, raising safety concerns. Here we aimed to evaluate the safety and immunogenicity of a skin- and neuro-attenuated varicella vaccine candidate (v7D).METHODS: This is a randomized, double-blind, placebo-controlled, dose-escalation and age de-escalation phase 1 clinical trial conducted in Liuzhou, China ...
Source: Herpes - June 7, 2023 Category: Infectious Diseases Authors: Zhao-Jun Mo Shou-Jie Huang Ling-Xian Qiu Chang-Gui Li Xiao-Juan Yu Ming-Qiang Li Zhen Chen Guo-Hua Zhong De-Quan Pan Li-Rong Huang Bang-Jun Lv Xue-Lian Cui Qiao-Qiao Song Ji-Zong Jia Jin-Le Han Wei Wang Hua Zhu Tong Cheng Ying-Ying Su Yi-Min Li Xiang-Zhon Source Type: research
Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study
In this study, we estimate the long-term health impacts of GH in the United States using quality-adjusted life years (QALYs) lost.METHODS: We used probability trees to model the natural history of GH secondary to infection with HSV-1 and HSV-2 among people aged 18-49 years. We modelled the following outcomes to quantify the major causes of health losses following infection: symptomatic herpes outbreaks, psychosocial impacts associated with diagnosis and recurrences, urinary retention caused by sacral radiculitis, aseptic meningitis, Mollaret's meningitis, and neonatal herpes. The model was parameterized based on published ...
Source: Herpes - March 23, 2023 Category: Infectious Diseases Authors: Shiying You Reza Yaesoubi Kyueun Lee Yunfei Li Samuel T Eppink Katherine K Hsu Harrell W Chesson Thomas L Gift Andr és A Berruti Joshua A Salomon Minttu M R önn Source Type: research
The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study
EBioMedicine. 2023 Mar 16;90:104530. doi: 10.1016/j.ebiom.2023.104530. Online ahead of print.ABSTRACTBACKGROUND: Evidence suggests HSV-2 infection increases HIV acquisition risk and HIV/HSV-2 coinfection increases transmission risk of both infections. We analysed the potential impact of HSV-2 vaccination in South Africa, a high HIV/HSV-2 prevalence setting.METHODS: We adapted a dynamic HIV transmission model for South Africa to incorporate HSV-2, including synergistic effects with HIV, to evaluate the impact of: (i) cohort vaccination of 9-year-olds with a prophylactic vaccine that reduces HSV-2 susceptibility; (ii) vaccin...
Source: Herpes - March 18, 2023 Category: Infectious Diseases Authors: Jack Stone Katharine Jane Looker Romain Silhol Katherine Mary Elizabeth Turner Richard Hayes Jenny Coetzee Stefan Baral Sheree Schwartz Philippe Mayaud Sami Gottlieb Marie-Claude Boily Peter Vickerman Source Type: research
Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study
This study aimed to assess the 'real-world' effectiveness of the zoster vaccine live (ZVL) against HZ and postherpetic neuralgia (PHN).METHODS: We conducted a nationwide retrospective matched cohort study from 1 April 2018 to 1 April 2021 using a linked de-identified patient level Ministry of Health data platform. A Cox proportional hazards model was used to estimate ZVL vaccine effectiveness (VE) against HZ and PHN adjusting for covariates. Multiple outcomes were assessed in the primary (hospitalised HZ and PHN - primary diagnosis) and secondary (hospitalised HZ and PHN: primary and secondary diagnosis, community HZ) anal...
Source: Herpes - March 7, 2023 Category: Infectious Diseases Authors: James F Mbinta Alex X Wang Binh P Nguyen Janine Paynter Prosper Mandela A Awuni Russell Pine Andrew A Sporle Colin R Simpson Source Type: research
Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions
This study characterized HSV-2 seroprevalence in Europe for various at-risk populations and proportions of HSV-2 detection in genital ulcer disease (GUD) and in genital herpes. Data on neonatal herpes and HSV-2's contribution to HIV transmission were also reviewed.METHODS: Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report HSV-2 related findings. The search was conducted in PubMed and Embase databases up to February 20, 2022. Any publication reporting data on the outcome measures was included. Meta-analyses and meta-regressions were conducted.FINDINGS: 211 relevant reports were id...
Source: Herpes - February 23, 2023 Category: Infectious Diseases Authors: Asalah Alareeki Aisha M M Osman Mohannad N Khandakji Katharine J Looker Manale Harfouche Laith J Abu-Raddad Source Type: research
Fight Aging! Newsletter, February 13th 2023
This study investigated whether taller Polish adults live longer than their shorter counterparts. Data on declared height were available from 848,860 individuals who died in the years 2004-2008 in Poland. To allow for the cohort effect, the Z-values were generated. Separately for both sexes, Pearson's r coefficients of correlation were calculated. Subsequently, one way ANOVA was performed.
The correlation between adult height and longevity was negative and statistically significant in both men and women. After eliminating the effects of secular trends in height, the correlation was very weak (r = -0.0044 in men and ...
Source: Fight Aging! - February 12, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
